On February 27, 2015 Novartis reported that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion for Zykadia (ceritinib) to treat adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib (Press release, Novartis, FEB 27, 2015, View Source [SID:1234502000]). If approved in the European Union (EU), Zykadia will be the first treatment option to address an unmet medical need for patients with ALK+ NSCLC previously treated with crizotinib.

“Patients with advanced ALK+ NSCLC have few options when their cancer does not respond to currently approved therapy,” said Alessandro Riva, MD, Global Head, Novartis Oncology Development and Medical Affairs. “As a leader in the development of precision oncology medicines, Novartis is committed to developing and bringing to market new treatments for patients with ALK+ NSCLC. This positive CHMP opinion for Zykadia brings us one step closer to providing the lung cancer community with new hope in the fight against this terrible disease.”

Each year, there are 1.6 million people diagnosed with lung cancer, the leading cause of cancer death worldwide. The most common type of lung cancer is NSCLC, accounting for 85-90% of all cases. Of those, 2-7% are driven by a rearrangement of the ALK gene, which increases the growth of cancer cells and can be identified by a molecular test of the cancer tumor. Despite significant treatment advances for patients with ALK+ NSCLC, disease progression is often inevitable and more treatment options are needed.

In the EU, the European Commission generally follows the recommendations of the CHMP and delivers its final decision within three months of the CHMP recommendation. The decision will be applicable to all 28 EU member states plus Iceland, Norway and Liechtenstein. Zykadia is currently approved in the United States, Mexico, Chile, South Korea, Guatemala and Ecuador. Additional regulatory reviews are underway in North America, South America, Central America and Asia.

The CHMP recommendation for Zykadia was based on results from two global, multicenter, open-label, single-arm studies (Study A and Study B). Comparative efficacy data from randomized clinical studies are not yet available. The primary efficacy endpoint for these studies was overall response rate (ORR), including complete response and partial response, for patients who were treated with a 750 mg dose of Zykadia, confirmed by repeat assessments performed not less than four weeks after the criteria for response was first met. Additional evaluations included duration of response (DOR) and progression-free survival (PFS) by investigator and blinded independent review committee (BIRC) assessment, and overall survival (OS). Tumor evaluations were performed according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.0 in Study A and RECIST 1.1 in Study B.

On February 27, 2015 Amgen reported that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion to extend the marketing authorization for Vectibix (panitumumab) to include combination with FOLFIRI (an irinotecan-based chemotherapy) as first-line treatment in adult patients with wild-type RAS metastatic colorectal cancer (mCRC) (Press release, Amgen, FEB 27, 2015, View Source [SID:1234501999]). About half of the patients with mCRC have wild-type RAS tumors.1

“Adding Vectibix to chemotherapy as first-line treatment in patients with wild-type RAS metastatic colorectal cancer has been shown to result in better responses than chemotherapy alone,” said Elliott M. Levy, M.D., senior vice president of Global Development at Amgen. “The CHMP recommendation is an important step toward increasing the treatment options for patients with this aggressive disease and helping improve outcomes in the European Union.”

The new indication is based upon the 20060314 study, which evaluated Vectibix plus FOLFIRI in the first-line setting. Vectibix is already approved in the European Union (EU) for the treatment of adult patients with wild-type RAS mCRC1:

in first-line in combination with FOLFOX.
in second-line in combination with FOLFIRI for patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan).
as monotherapy after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.

The CHMP positive opinion will now be ratified by the European Commission who, should they affirm the CHMP opinion, will extend the centralized marketing authorization which is valid in the 28 countries that are members of the EU, as well as European Economic Area members, Iceland, Lichtenstein and Norway.

The safety profile of Vectibix was consistent with previously reported studies.

Colorectal cancer is the third most common cancer worldwide, with approximately 1.2 million cases expected to occur globally.2,3 The highest estimated mortality rates associated with colorectal cancer occur in Central and Eastern Europe.